News: CytoDyn’s Phase 2 Study of Leronlimab for
Post# of 151637
(Total Views: 855)
Posted On: 09/23/2020 1:37:10 AM
News: CytoDyn’s Phase 2 Study of Leronlimab for Mild-to-Moderate COVID-19 Selected for Oral Presentation at the Special isirv-AVG Virtual Conference on ‘Therapeutics for COVID-19’
Download as PDFSeptember 23, 2020 12:53am EDT
VANCOUVER, Washington, Sept. 22, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the Phase 2 study of leronlimab for mild-to-moderate COVID-19 patients has been selected for an oral presentation at the upcoming Special isirv-Antiviral Group Conference on ‘Therapeutics for COVID-19.’ The Conference is sponsored by the International Society for Influenza and other Respiratory Virus Diseases, an independent and international scientific professional society promoting the prevention, detection, treatment, and control of influenza and other respiratory virus disease.
Details of the presentation are as follows:
Abstract Title: “A Phase 2 Study of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19).”
Abstract Confirmation Number: AAVGV0010
Presenter: Harish Seethamraju, M.D., Medical Director, Advanced Lung Failure and Lung Transplant, Montefiore Medical Center, Bronx, New York.
Presentation Date and Time: October 6-8, 2020 12.00-4.00pm GMT and will be available on demand.
Additional details can be found on the conference web site here
“The acceptance of this oral abstract by this highly regarded scientific organization is very rewarding for all of the medical professionals who provided care and treatment to the COVID-19 patients during our Phase 2 trial. We also view this acceptance as a validation of leronlimab as a potential therapeutic for this disease and we look forward to the upcoming interim analysis from our Phase 3 trial for severe-to-critical COVID-19 patients,” said Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn.
https://www.cytodyn.com/newsroom/press-releas...nlimab-for
Download as PDFSeptember 23, 2020 12:53am EDT
VANCOUVER, Washington, Sept. 22, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the Phase 2 study of leronlimab for mild-to-moderate COVID-19 patients has been selected for an oral presentation at the upcoming Special isirv-Antiviral Group Conference on ‘Therapeutics for COVID-19.’ The Conference is sponsored by the International Society for Influenza and other Respiratory Virus Diseases, an independent and international scientific professional society promoting the prevention, detection, treatment, and control of influenza and other respiratory virus disease. Details of the presentation are as follows:
Abstract Title: “A Phase 2 Study of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19).”
Abstract Confirmation Number: AAVGV0010
Presenter: Harish Seethamraju, M.D., Medical Director, Advanced Lung Failure and Lung Transplant, Montefiore Medical Center, Bronx, New York.
Presentation Date and Time: October 6-8, 2020 12.00-4.00pm GMT and will be available on demand.
Additional details can be found on the conference web site here
“The acceptance of this oral abstract by this highly regarded scientific organization is very rewarding for all of the medical professionals who provided care and treatment to the COVID-19 patients during our Phase 2 trial. We also view this acceptance as a validation of leronlimab as a potential therapeutic for this disease and we look forward to the upcoming interim analysis from our Phase 3 trial for severe-to-critical COVID-19 patients,” said Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn.
https://www.cytodyn.com/newsroom/press-releas...nlimab-for
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼